XML 90 R53.htm IDEA: XBRL DOCUMENT
v3.20.4

Note 11 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($) $ in Thousands |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 67 Months Ended | 69 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 03, 2020 | Mar. 04, 2020 | Nov. 05, 2019 | Sep. 06, 2018 | Jun. 16, 2015 | Aug. 31, 2020 | Jun. 30, 2006 | Jun. 30, 2000 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2020 | Dec. 31, 2020 | Mar. 31, 2015 | Nov. 11, 2011
Revenue from Contract with Customer, Including Assessed Tax |  |  |  |  |  |  |  |  | $ 4,016 | $ 6,102 | $ 2,871 | $ 4,823 | $ 39,725 | $ 1,775 | $ 1,448 | $ 5,887 |  | $ 17,812 | $ 48,835 | $ 20,653 |  |  |  |
Arbitration Proceedings of SUL Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement, Amount Awarded from Other Party |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Arbitration Proceedings of SUL Agreement [Member] | Other Income [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) Related to Litigation Settlement, Total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,893 |  |  |  |  |  |
Arbitration Proceedings of SUL Agreement [Member] | Selling, General and Administrative Expenses [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal Fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,026 |  |  |  |  |  |  |
US Department of Health and Human Services [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreement Contract Value |  |  |  | $ 34,660 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract Term (Year) |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Collaborators | $ 6,932 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,864 |  |  |  |  |
Torii Pharmaceutical Co. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront Payments Receivable Amount |  |  | $ 22,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021 |  |  | $ 15,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum Customary Reduction on Royalty Rate |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Payments Receivable, Expiration Term From First Commercial (Year) |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Including Assessed Tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,101 |  |  |  |  |
Contract with Customer, Liability, Revenue Recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,899 |  |  |  |  |  |
Torii Pharmaceutical Co. [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Including Assessed Tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 19,344 |  |  |  |  |
Torii Pharmaceutical Co. [Member] | Service [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Including Assessed Tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 757 |  |  |  |  |  |
Torii Pharmaceutical Co. [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Rate if Maintains Sakigake Designation |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Torii Pharmaceutical Co. [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Rate if Maintains Sakigake Designation |  |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CSL Limited [Member |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from License Fees Received |  |  |  |  | $ 33,740 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment Received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,000 |  |  |
Base Contract [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Government Contract Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 16,265 |
Additional Development Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Government Contract Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,855 |
ASPRBARDA Contract [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Government Contract Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 39,120 |
Proceeds from awards for Research and Development Contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,574 |  |
Green Cross Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from License Fees Received |  |  |  |  |  |  | $ 250 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mundipharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential Milestone Payments Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000
AECOM and IRL [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment Minimum |  |  |  |  |  |  |  | $ 1,400 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment Maximum |  |  |  |  |  |  |  | 4,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual License Fee Minimum |  |  |  |  |  |  |  | 150 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual License Fee Maximum |  |  |  |  |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
National Institute of Allergy and Infectious Diseases [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected Receivable From Awards for Research and Development Contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 45,931 |  |  |  |  |  |
Collaborative Agreement Contract, Covenant, Maximum Amount of Funding |  |  |  |  |  | $ 43,908 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreement Contract Value |  |  |  |  |  | $ 6,326 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
UAB [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of Agreement (Year) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25 years |  |  |  |  |  |
Renewable Period of Agreement (Year) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |

X
- Definition Represents annual maximum license fee. + References No definition available. + Details
Name: | bcrx_AnnualLicenseFeeMaximum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represent minimum annual license fee. + References No definition available. + Details
Name: | bcrx_AnnualLicenseFeeMinimum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents collaborative agreement contract value. + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementContractValue
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period of time between the contract date and its expiration. + References No definition available. + Details
Name: | bcrx_ContractTerm
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents expected receivable from awards for research and development contracts. + References No definition available. + Details
Name: | bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum percentage of customary reductions allowed on royalty rate. + References No definition available. + Details
Name: | bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix: | bcrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents milestone payment maximum. + References No definition available. + Details
Name: | bcrx_MilestonePaymentMaximum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents milestone payment minimum. + References No definition available. + Details
Name: | bcrx_MilestonePaymentMinimum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of milestone payment received. + References No definition available. + Details
Name: | bcrx_MilestonePaymentReceived
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents period of agreement. + References No definition available. + Details
Name: | bcrx_PeriodOfAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents potential milestone payments receivable based on possibility of future event payments. + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsReceivable
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021. + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents proceeds from awards for research and development contracts. + References No definition available. + Details
Name: | bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents renewable period of agreement. + References No definition available. + Details
Name: | bcrx_RenewablePeriodOfAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The expiration term of the royalty payments from first commercial date. + References No definition available. + Details
Name: | bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review. + References No definition available. + Details
Name: | bcrx_RoyaltyRateIfMaintainsSakigakeDesignation
Namespace Prefix: | bcrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents upfront payments receivable. + References No definition available. + Details
Name: | bcrx_UpfrontPaymentsReceivableAmount
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of receivables that are derived from government contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118261985&loc=d3e55295-109406 + Details
Name: | us-gaap_GovernmentContractReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount awarded from other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_CSLLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |